Nasdaq:TWIN
TWIN DISC INC
A US-based orthopedic innovator delivering premium joint reconstruction implants through an efficient direct-to-patient sales model with strong regional market presence.
Key Metrics
Investment Thesis
Bull Case
The company demonstrates impressive top-line growth with revenue surging from $277M to $340.7M over the last three years, suggesting successful product adoption and market expansion. Positive operating profit of $9.9M indicates underlying business efficiency that can potentially be leveraged to restore net income once one-time charges or restructuring costs normalize. The direct sales model offers a structural cost advantage that could help maintain profitability in a high-cost medical device environment.
Bear Case
The transition from profitable operations in 2024 to a net loss in 2025 raises serious concerns about the sustainability of current growth and the company's ability to manage expenses. Significant revolver repayments of $122.3M and other financing outflows of $125.5M indicate heavy reliance on debt or refinancing, which could strain liquidity if credit conditions tighten. A retained earnings deficit of $125.4M highlights a history of accumulated losses that must be addressed before the stock can be considered a stable investment.
About TWIN DISC INC
TWIN DISC INC specializes in designing, manufacturing, and marketing orthopedic implant solutions primarily serving the North American healthcare market. The company focuses on joint reconstruction products, including hip, knee, and shoulder implants, leveraging a direct-to-patient sales model to streamline distribution and reduce intermediary costs. With recent revenue growth driven by product innovation and expanded surgical volume, TWIN aims to capture market share against larger global competitors while maintaining operational efficiency.
Analysis
Management Discussion
While revenue expanded significantly by 15% in 2025 to $340.7M, reflecting strong top-line growth, profitability deteriorated sharply with a net loss of $1.6M compared to prior years of positive earnings. Operating expenses rose alongside general and administrative costs, partially offsetting the gross profit increase generated by higher revenue volumes. Cash flow from operations remained robust at $24.0M, providing liquidity to fund capital expenditures of $15.2M despite a net decrease in cash balance.
Industry Overview
The global orthopedic implant market is highly competitive, dominated by large multinational corporations with extensive R&D pipelines and global distribution networks. Regulatory approvals from bodies like the FDA are stringent and costly, creating high barriers to entry but also protecting established players who have cleared these hurdles. Technological advancements in materials science and minimally invasive surgical techniques continue to drive demand for premium implant solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $277.0M | $295.1M | $340.7M |
| Cost of Revenue | $202.6M | $211.8M | $248.0M |
| Gross Profit | $74.3M | $83.3M | $92.7M |
| Operating Expenses | $58.3M | $71.8M | $82.8M |
| Operating Income | $16.1M | $11.5M | $9.9M |
| R&D | $2.5M | $2.6M | $2.7M |
| G&A | $62.2M | $71.6M | $82.4M |
| D&A | $9.4M | $10.0M | $14.9M |
| Depreciation | $6.4M | $6.7M | $10.0M |
| Amortization | $3.0M | $3.3M | $4.0M |
| Other OpEx | $-6.4M | $-2.4M | $-2.3M |
| Non-Operating Income | $-1.6M | $3.9M | $-8.1M |
| Interest Expense | $2.3M | $1.4M | — |
| Interest Income | $33.0K | $64.0K | $67.0K |
| Pre-Tax Income | $14.5M | $15.4M | $1.8M |
| Income Tax | $3.8M | $4.1M | $3.4M |
| Continuing Ops | $10.7M | $11.2M | $-1.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $10.7M | $11.2M | $-1.6M |
| Minority Interest | $297.0K | $258.0K | $295.0K |
| Net to Common | $10.4M | $11.0M | $-1.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $219.7M | $219.6M | $246.9M |
| Accounts Receivable | $54.8M | $52.2M | $58.9M |
| Inventory | $131.9M | $130.5M | $152.0M |
| Other Current Assets | $33.0M | $36.9M | $36.0M |
| Long-Term Assets | $69.5M | $92.4M | $108.6M |
| PP&E (Net) | $38.6M | $58.1M | $69.6M |
| Intangibles | $12.6M | $12.7M | $13.4M |
| Goodwill | $0 | — | $2.9M |
| Operating Leases | $13.1M | $16.6M | $17.2M |
| Other LT Assets | $5.1M | $5.0M | $5.6M |
| Total Assets | $289.2M | $312.1M | $355.6M |
| Current Liabilities | $100.1M | $99.5M | $125.8M |
| Accounts Payable | $36.5M | $32.6M | $38.7M |
| Current Debt | $2.0M | $2.0M | $3.0M |
| Current Leases | — | $2.4M | $3.4M |
| Deferred Revenue | $22.9M | $26.5M | $43.2M |
| Other Current Liab | $-22.9M | $-28.9M | $-43.2M |
| Long-Term Liabilities | $43.6M | $57.5M | $65.4M |
| Long-Term Debt | $16.6M | $23.8M | $28.4M |
| LT Operating Leases | $10.8M | $14.4M | $14.4M |
| Other LT Liab | $16.1M | $19.3M | $22.6M |
| Total Liabilities | $143.7M | $157.0M | $191.2M |
| Shareholders' Equity | $145.5M | $155.1M | $164.4M |
| Retained Earnings | $120.3M | $129.6M | $125.4M |
| AOCI | $-5.6M | $-6.9M | $3.7M |
| Total L&E | $289.2M | $312.1M | $355.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $10.7M | $11.2M | $-1.6M |
| Non-Cash Adjustments | $-13.5M | $47.7M | $2.1M |
| Working Capital Changes | $25.8M | $-25.2M | $23.4M |
| Cash from Operations | $22.9M | $33.7M | $24.0M |
| Capital Expenditures | $7.9M | $8.7M | $15.2M |
| Cash from Investing | $-408.0K | $-32.1M | $-32.9M |
| Dividends Paid | — | $1.7M | $2.3M |
| Cash from Financing | $-19.5M | $2.8M | $-965.0K |
| FX Effect | $-2.2M | $2.4M | $5.9M |
| Net Change in Cash | $742.0K | $6.8M | $-4.0M |
| Beginning Cash | $12.5M | $13.3M | $20.1M |
| Ending Cash | $13.3M | $20.1M | $16.1M |
Frequently Asked Questions
How does TWIN DISC INC make money?
Primary revenue streams include hip system implants, knee reconstruction solutions, and shoulder stabilization products. Additional segments encompass sports medicine instrumentation and associated surgical accessories that support orthopedic surgeons in various clinical settings.
What are the main risks for TWIN?
Significant revenue concentration in the US market exposes the company to potential regulatory changes or reimbursement policy shifts within that single geography. Recent financial data shows a sharp decline from positive net income in 2024 to a loss in 2025, indicating potential pressure on margins or volume growth sustainability. High capital expenditures and revolver repayments suggest ongoing liquidity stress or significant restructuring costs impacting cash flow. Intense competition from established global giants could erode market share if the company cannot sustain its pricing power.
What is TWIN's competitive advantage?
Direct-to-patient sales model eliminates distributor markups, improving gross margins and allowing for more competitive pricing structures. Proprietary implant designs offer superior fixation and wear characteristics compared to legacy products, driving surgeon preference. Agile manufacturing capabilities allow rapid response to specific regional market demands without the overhead of a massive global footprint.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.